Terminated PHASE3 INTERVENTIONAL 2-arm NCT00082095

To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older

A Randomized, Open-Label Trial Comparing Treatment With Either Pegylated Liposomal Doxorubicin or Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer in Women 60 Years and Older

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions Metastatic Breast Cancer

Interventions Capecitabine Pegylated liposomal doxorubicin

Updated 11 times since 2017 Last updated: Oct 8, 2014 Started: Apr 30, 2004 Primary completion: Dec 31, 2005 Completion: Dec 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated due to poor recruitment (after enrolling 62 of planned 300 patients in 20 months

Other terminated trials from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

More terminations from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Other Metastatic Breast Cancer trials with similar outcome

Browse all Metastatic Breast Cancer trials

This PHASE3 trial investigates Metastatic Breast Cancer and is currently terminated or withdrawn. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. leads this study, which shows 11 recorded versions since 2004 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 6 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE3
May 2018 — Jun 2018 [monthly]

Terminated PHASE3
Aug 2017 — May 2018 [monthly]

Terminated PHASE3
Feb 2017 — Aug 2017 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Data source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Armonk, United States , Atlanta, United States , Baltimore, United States , Boca Raton, United States , Burlington, United States , Clinton Township, United States , Colchester, United States , Everett, United States , Fort Worth, United States and 17 more locations